214 related articles for article (PubMed ID: 31868151)
1. FDG PET/CT in the Staging of Lung Cancer.
Farsad M
Curr Radiopharm; 2020; 13(3):195-203. PubMed ID: 31868151
[TBL] [Abstract][Full Text] [Related]
2. Thoracic staging with
Schaarschmidt BM; Grueneisen J; Metzenmacher M; Gomez B; Gauler T; Roesel C; Heusch P; Ruhlmann V; Umutlu L; Antoch G; Buchbender C
Eur Radiol; 2017 Feb; 27(2):681-688. PubMed ID: 27180186
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
[TBL] [Abstract][Full Text] [Related]
4. Is there any improvement in clinical staging with
Gedik GK; Yilmaz F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(6):348-354. PubMed ID: 31378538
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET/Contrast-Enhanced CT for Initial Staging and Strategic Treatment of Non-Small Cell Lung Cancer: A Prospective Study.
Promteangtrong C; Kunawudhi A; Phadungrerk R; Iamsa-art C; Chotipanich C
J Med Assoc Thai; 2015 Oct; 98(10):1010-8. PubMed ID: 26638593
[TBL] [Abstract][Full Text] [Related]
6. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
[TBL] [Abstract][Full Text] [Related]
8. Impact of
Al-Ibraheem A; Hirmas N; Fanti S; Paez D; Abuhijla F; Al-Rimawi D; Al-Rasheed U; Abdeljalil R; Hawari F; Alrabi K; Mansour A
BMC Med Imaging; 2021 Mar; 21(1):49. PubMed ID: 33731050
[TBL] [Abstract][Full Text] [Related]
9. Value of positron emission tomography for lung cancer staging.
Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G
Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
[TBL] [Abstract][Full Text] [Related]
10. Utility of FDG PET/CT for Preoperative Staging of Non-Small Cell Lung Cancers Manifesting as Subsolid Nodules With a Solid Portion of 3 cm or Smaller.
Suh YJ; Park CM; Han K; Jeon SK; Kim H; Hwang EJ; Lee JH; Paeng JC; Lee CH; Kim YT; Goo JM
AJR Am J Roentgenol; 2020 Mar; 214(3):514-523. PubMed ID: 31846374
[No Abstract] [Full Text] [Related]
11. Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PET/CT in patients with non small cell lung cancer scheduled for radiotherapy--a retrospective study.
Abramyuk A; Appold S; Zöphel K; Hietschold V; Baumann M; Abolmaali N
Lung Cancer; 2012 Nov; 78(2):148-52. PubMed ID: 22922126
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
13. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma.
Poncelet AJ; Lonneux M; Coche E; Weynand B; Noirhomme P;
Eur J Cardiothorac Surg; 2001 Sep; 20(3):468-74; discussion 474-5. PubMed ID: 11509265
[TBL] [Abstract][Full Text] [Related]
14. Prospective preoperative mediastinal lymph node staging by integrated positron emission tomography-computerised tomography in patients with non-small-cell lung cancer.
Perigaud C; Bridji B; Roussel JC; Sagan C; Mugniot A; Duveau D; Baron O; Despins P
Eur J Cardiothorac Surg; 2009 Oct; 36(4):731-6. PubMed ID: 19632852
[TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of
Kirchner J; Sawicki LM; Nensa F; Schaarschmidt BM; Reis H; Ingenwerth M; Bogner S; Aigner C; Buchbender C; Umutlu L; Antoch G; Herrmann K; Heusch P
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):437-445. PubMed ID: 30074073
[TBL] [Abstract][Full Text] [Related]
16. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer.
Berlangieri SU; Scott AM; Knight SR; Fitt GJ; Hennessy OF; Tochon-Danguy HJ; Clarke CP; McKay WJ
Eur J Cardiothorac Surg; 1999 Sep; 16 Suppl 1():S25-30. PubMed ID: 10536941
[TBL] [Abstract][Full Text] [Related]
17. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.
Vaarwerk B; Breunis WB; Haveman LM; de Keizer B; Jehanno N; Borgwardt L; van Rijn RR; van den Berg H; Cohen JF; van Dalen EC; Merks JH
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012325. PubMed ID: 34753195
[TBL] [Abstract][Full Text] [Related]
18. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E
Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985
[TBL] [Abstract][Full Text] [Related]
19. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J
Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365
[TBL] [Abstract][Full Text] [Related]
20. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
